Chongqing Zhifei Biological Products Co.Ltd(300122) 3 announced on March 16 that the company recently learned that the “23 valent pneumococcal polysaccharide vaccine” developed by its wholly-owned subsidiary – Beijing Zhifei Lvzhu biopharmaceutical Co., Ltd. applied for production registration and obtained the acceptance notice issued by the State Drug Administration.
The data show that Streptococcus pneumoniae is the most important pathogen causing community-acquired pneumonia in all age groups, and it is also the main pathogen causing otitis media, pneumonia, meningitis and bacteremia. According to the statistics of the World Health Organization, more than 1.2 million people worldwide die of Streptococcus pneumoniae infection every year, most of which occur in developing countries. The vaccine for prevention of pneumococcal infection is divided into 2 kinds: polysaccharide vaccine and conjugate vaccine. Among them, 23-Valent Pneumococcal Polysaccharide Vaccine is used for the prevention of pneumococcal infectious diseases among people over 2 years old. It is one of the most important products for preventing pneumococcal infection outside China.
Chongqing Zhifei Biological Products Co.Ltd(300122) said that at present, 23 price pneumococcal polysaccharide vaccine products have been listed outside China. If the project goes smoothly, it will further give play to the advantages of the company’s pneumonia vaccine matrix, improve the product echelon, and have a positive impact on future operation, R & D innovation and long-term sustainable development.
At the same time, the company also suggests that after the application for production registration of the project is accepted, it can only be approved after relevant review procedures such as technical review, clinical trial on-site verification and production on-site inspection, and its progress and results are uncertain.
